Navigation Links
VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013
Date:2/5/2013

NEW YORK, Feb. 5, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013

http://www.reportlinker.com/p0656768/VEGF-Inhibition-Therapy-Indicating-and-Prognostic-Biomarkers-2013.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics

 

Vascular Endothelial Growth Factor (VEGF), which plays an important role in angiogenesis, has been extensively studied and over-expression is seen in many cancers. Today, VEGF is targeted using antibodies and tyrosine kinase inhibitors, and antiangiogenic therapy is a standard treatment for many cancers, including colorectal and non-small cell lung cancer.

 

While VEGF inhibitors such as bevacizumab (Avastin®) provide valuable treatment options, these benefits are not seen in all patients and cancer types. Today, there is an urgent need for predictive biomarkers to enable those patients most likely to benefit from VEGF inhibition, to be identified. This report provides a review of findings to date on biomarkers associated with the use bevacizumab (Avastin®); both therapy-indicating and prognostic.

 

The identification of therapy-indicating and prognostic biomarkers relating to antiangiogenic therapy is in its early stages, however important advances have been made. This report identifies the latest findings on ten different cancers and includes an evaluation of candidate biomarkers as a basis for interpreting patient outcomes according to RECIST criteria, and evaluates existing bevacizumab-containing treatments and drug combinations.

 

Key content:

• A comprehensive review of clinical studies that have identified biomarkers that are either therapy-indicating in respect of bevacizumab (Avastin®) or indicative of patient prognosis

• Biomarkers identified or further evaluated in the last five years, up until January 2013. From a background of extensive research on bevacizumab (Avastin®) and VEGF-related biomarkers, the most important findings have been identified for their significance and value to patients and in designing clinical trials

• Covering more than ten cancers including colorectal, ovarian, renal, breast, pancreatic, prostate, lung and liver cancers

• Findings based on clinical trial findings including patient numbers, statistics and RECIST criteria

• Studies indicate drug type associations together with comparative therapies

• Descriptions and explanation of all biomarkers identified (proteins, genotypes, imaging etc)

• Biomarker associations are categorised according to three broad criteria, namely "positive-therapy-indicating" (response, improved response, improved outcome or prognosis), "non-therapy-indicating" (no differences in tumour response, outcome or prognosis) and "negative-therapy-indicating" (adverse events, poor outcome or prognosis).

 

 

 

Executive Summary

 

Chapter 1: Background (p.18)

 

1.1 VEGF Inhibition

1.2 Bevacizumab

1.3 Biomarkers

1.4 This Report

 

Chapter 2 Colorectal Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies (p. 22)

 

Summary

2.1 Introduction

2.2 Glycoprotein

2.3 Protein

2.4 Protein

2.5 Cells

2.6 Genetic

2.7 Physical

2.8 Genetic

2.9 Protein

2.10 Proteins

2.11 Proteins and Genetic

2.12 Image

2.13 Proteins

2.14 Protein

 

Chapter 3 Breast Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies (p.42)

 

Summary

3.1 Introduction

3.2 Protein

3.3 Protein

3.4 Protein

3.5 Protein

3.6 Protein

3.7 Genetic

3.8 Protein

 

Chapter 4 Renal Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies (p.50)

 

Summary

4.1 Introduction

4.2 Image

4.3 Protein

4.4 Physical

4.5 Protein

4.6 Body Characteristic

 

Chapter 5 Ovarian Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies (p.55)

 

Summary

5.1 Introduction

5.2 Proteins

5.3 Proteins

5.4 Proteins

5.5 Proteins

 

Chapter 6 Lung Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies (p.60)

 

Summary

6.1 Introduction

6.2 Physical Parameter

6.3 Protein

6.4 Genetic

6.5 Protein

 

Chapter 7 Liver Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies (p.65)

 

Summary

7.1 Introduction

7.2 Protein

7.3 Image

 

Chapter 8 Other Cancers: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies (p.71)

 

Summary

8.1 Introduction

8.2 Proteins

8.3 Proteins

8.4 Protein

8.5 Protein

8.6 Physical

8.7 Physical

8.8 Physical

 

Chapter 9: Discussion (p.80)

 

9.1 Overview

9.2 Colorectal Cancer

9.3 Breast Cancer:

9.4 Renal Cancer:

9.5 Ovarian Cancer

9.6 Lung Cancer

9.7 Liver Cancer

9.8 Other Cancers

9.9 Conclusions

 

 

 

Tables

 

Table 2.1 Candidates biomarkers identified in colorectal cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 3.1 Candidates biomarkers identified in breast cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 4.1 Candidates biomarkers identified in renal cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 5.1 Candidates biomarkers identified in ovarian cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 6.1 Candidates biomarkers identified in lung cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 7.1 Candidates biomarkers identified in liver cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 8.1 Candidates biomarkers identified in other cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 9.1 Protein candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 9.2 Genetic candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 9.3 Image-based candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Table 9.4 Other candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

 

 

 

Figures

 

Figure 9.1 Candidate biomarkers types identified in cancer patients receiving bevacizumab-containing therapies

Figure 9.2 Cancer types evaluated for biomarkers identified in cancer patients receiving bevacizumab-containing therapies

Figure 9.3 Author countries (identified in this report) of cancers evaluated for biomarkers identified in cancer patients receiving bevacizumab-containing therapies

 

 

 

To order this report:

Genomics Industry: VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013

 

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Study confirms prognostic value of new IASLC/ATS/ERS adenocarcinoma sub-classification
2. Game changing diagnostic & prognostic prostate cancer genetic tests revealed by Jefferson
3. EGFR mutation not prognostic factor in non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at ... between startups and global businesses, taking place in ... startups will showcase the solutions they have built with IBM ... France is one of the most ... increase in the number of startups created between 2012 and ...
(Date:4/24/2017)... , April 24, 2017 Janice ... partner with  Identity Strategy Partners, LLP (IdSP) , ... or without President Trump,s March 6, 2017 ... Entry , refugee vetting can be instilled with greater ... (Right now, all refugee applications are suspended by ...
(Date:4/13/2017)... , April 13, 2017 According to a ... Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment ... the IAM Market is expected to grow from USD 14.30 Billion in ... Rate (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... ... of a complex biological network, a depiction of a system of linkages and ... Dmitry Korkin, PhD, associate professor of computer science at Worcester Polytechnic Institute (WPI) ...
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont Pioneer ... that they have entered into a multiyear collaboration to identify and characterize novel ... additional tools for gene editing across all applications. , Under the terms of ...
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces expanded ... of its newest module, US Hemostats & Sealants. , SmartTRAK’s US Market for ... fibrin sealants, synthetic sealants and biologic sealants used in surgical applications. BioMedGPS estimates ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... launched Rosalind™, the first-ever genomics analysis platform specifically designed for life science ... in honor of pioneering researcher Rosalind Franklin, who made a major contribution ...
Breaking Biology Technology: